CardioSignal
CardioSignal is a Finland-based digital health company offering a CE-marked Class IIb medical device app that uses patented gyrocardiography technology to detect atrial fibrillation and heart failure via smartphone motion sensors, serving consumers, healthcare providers, insurers, and pharma/CROs.
- Company typePrivate
- Founded2017
- HeadquartersTurku, Finland
- Headcount11–50
- GTM typeB2B and B2C
- OfferingSoftware
What CardioSignal does
CardioSignal (operating legal entity Precordior Ltd) is a Finland-based digital health company founded in 2017 as a University of Turku spin-off that develops a CE-marked Class IIb medical device mobile application for cardiac diagnostics. The product is built on proprietary gyrocardiography technology, which uses a smartphone's gyroscope and accelerometer to measure rotational heart motion during a one-minute measurement and applies a clinically validated algorithm to detect signs of atrial fibrillation, with 95.3% sensitivity and 96.0% specificity reported in clinical studies. The same method has demonstrated 89% diagnostic accuracy for heart failure detection in a multicenter study of over 1,000 participants published in JACC: Heart Failure. The IP base comprises 52 patents and 20+ peer-reviewed publications backed by 12+ years of academic research.
The company operates a hybrid revenue model. On the consumer side, the CardioSignal app is sold via subscription through Apple App Store and Google Play at €6.99/month, €17.99/quarter, or €44.99/year across 15 European countries, with 200,000+ users to date. On the B2B side, the company licenses its detection technology through "CardioSignal Inside," an SDK that lets partners embed CE-marked Afib detection into their own mobile applications (CardioSignal retains regulatory responsibility as legal manufacturer), and runs population health programs with insurance companies (LocalTapiola, DKV), healthcare providers (Mehiläinen, Heart Center Mølholm), and device manufacturers (OMRON Healthcare). Additional segments include pharma/CROs for clinical-trial digital endpoints and point-of-care clinical use.
CardioSignal has raised $23 million in total funding (€2.2M seed from Maki.vc in September 2021; $10M Series A led by DigiTx Partners in January 2024 with Sandwater and Maki.vc). The company is headquartered in Turku, Finland with a US subsidiary (CardioSignal Inc.) in Palo Alto, California, and is certified to ISO 13485 (medical device quality) and ISO 27001 (information security). The leadership team combines clinical cardiology (CEO Dr. Juuso Blomster, Medical Director Dr. Blaž Mrevlje), biosignal engineering (CTO Ilkka Korhonen), and corporate governance credibility (board members Ursula Burns and David J. Kim).
CardioSignal firmographics
Firmographics- Name
- CardioSignal
- Legal name
- Precordior Ltd
- Website
- https://cardiosignal.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CardioSignal is a Finland-based digital health company offering a CE-marked Class IIb medical device app that uses patented gyrocardiography technology to detect atrial fibrillation and heart failure via smartphone motion sensors, serving consumers, healthcare providers, insurers, and pharma/CROs.
- Ownership category
- akta.pro rank
CardioSignal industry classification
Industry- Product category
- Digital Cardiac Diagnostics Software
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Cardiology Telemedicine Platforms (HLALAGAB)
- akta.pro secondary industries
- Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), ECG/EKG & Heart Rhythm Monitors (Consumer) (CRACAQAC), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)
Keywords
Where CardioSignal is headquartered
LocationHeadquarters
- HQ city
- Turku
- HQ country
- Finland
- HQ region
- Europe
Offices2 records
Markets served
CardioSignal business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Consumer App Subscriptions: Direct-to-consumer subscription model through Apple App Store and Google Play. Subscribers pay monthly, quarterly, or annual fees to access the CardioSignal app for self-monitoring of atrial fibrillation. Auto-renewing subscriptions managed through app store billing systems.
- SDK Licensing (CardioSignal Inside): B2B licensing model where partners integrate CardioSignal's CE-marked atrial fibrillation detection technology into their own mobile applications via SDK. Partners include healthcare providers, insurance companies, and app developers who embed medical-grade Afib detection without building their own regulated product.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Monthly subscription for individual self-monitoring |
| Subscription | Pay-as-you-go | Quarterly subscription for individual self-monitoring |
| Subscription | Annual | Annual subscription for individual self-monitoring |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels7 records
CardioSignal product offering
Product offeringCore offering
CardioSignal develops a CE-marked Class IIb mobile medical device software that uses smartphone gyroscope and accelerometer sensors via patented gyrocardiography to measure heart motion and detect signs of atrial fibrillation in a one-minute measurement. The company sells directly to individual consumers through a subscription app and licenses its detection technology to enterprise partners (healthcare providers, insurers, pharma/CROs, and OEMs) through its CardioSignal Inside SDK for population screening, remote patient monitoring, and clinical trial endpoints.
Product overview
CardioSignal is a single unified mobile medical device product built on patented gyrocardiography technology that detects atrial fibrillation using a smartphone's built-in gyroscope and accelerometer. The core CardioSignal App is a CE-marked Class IIb medical device offered to consumers via subscription, with four deployment variants: Self-Monitoring (direct-to-consumer), Population Health Programs (for care providers and insurers), Point-of-Care Solutions (for clinical settings), and Pharma/CROs (for clinical trials). A complementary B2B offering called CardioSignal Inside is an SDK that enables partners to embed CardioSignal's CE-marked AFib detection into their own apps — as demonstrated in the OMRON connect app partnership. The product portfolio is completed by a Whitepaper resource on population health program implementation.
Differentiator
Problem solved
Functional benefit
Products and services
- CardioSignal App (Self-Monitoring) A CE-marked Class IIb medical device mobile application that uses smartphone motion sensors (gyroscope and accelerometer) to detect signs of atrial fibrillation in a 1-minute measurement, with clinically validated sensitivity of 95.3% and specificity of 96.0%. Targeted at individual consumers aged 18+ with risk factors (age, family history, hypertension, diabetes). Available via subscription (EUR 6.99/month, EUR 17.99/quarter, EUR 44.99/year) on iOS and Android in 15 European countries.
- CardioSignal Inside SDK An SDK (software development kit) that allows B2B partners to embed CardioSignal's CE-marked atrial fibrillation detection and heart rate measurement into their own mobile applications as native features, without partners having to develop or certify their own regulated medical product. Regulatory responsibility remains with CardioSignal as legal manufacturer.
- Population Health Programs A digital atrial fibrillation detection program for care providers, hospitals, clinics, and insurance companies to implement targeted or population-wide atrial fibrillation screening and remote patient monitoring initiatives. Deployed via insurance-sponsored access (LocalTapiola, DKV) and healthcare-provider-sponsored access (Mehiläinen, Heart Center Mølholm) covering thousands of individuals per program.
- Point-of-Care Solutions Clinical point-of-care atrial fibrillation detection offering for healthcare institutions, designed to reduce atrial fibrillation-related burden in clinical practice and enable primary-care physicians to screen for heart disease using a smartphone during patient visits.
- Pharma and CRO Cardiac Monitoring CardioSignal's cardiac detection technology offered to pharmaceutical companies and Contract Research Organizations (CROs) for use as digital biomarkers and endpoints in clinical trials, drug development programs, and patient monitoring studies.
Quantifiable outcome
- 95-97% accuracy in detecting atrial fibrillation
- +3 more outcomes
Companies that use CardioSignal
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
CardioSignal technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature4 records
CardioSignal partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- DKVcoreLeading private health insurer in Spain (part of ERGO Group) selected CardioSignal as winner of Desafio DKV 2025 innovation challenge. Partnership to integrate smartphone-based Afib detection into DKV's digital health ecosystem for insured customers.
- LocalTapiolacoreFinnish insurance company launched pilot program offering 5,000 customers aged 50-75 free access to CardioSignal for six months for atrial fibrillation screening. Partnership aims to prevent strokes through early detection.
- Heart Center MolholmcoreDenmark's esteemed private hospital and cardiac ablation pioneer offering 12 months of complimentary CardioSignal access to patients post-ablation. Partnership enhances patient recovery monitoring and early arrhythmia relapse detection.
- European Society of CardiologyminorCardioSignal presented clinical data at ESC 2024 annual meeting in London on atrial fibrillation detection reliability. CEO Dr. Juuso Blomster presented in Transforming Population Health session.
- MehilainencoreNordic private healthcare provider continues population health program with 10,000 individuals for atrial fibrillation detection. Previously successfully engaged 8,500 individuals in 3 weeks with 93% user satisfaction.
- AgeTech Collaborative from AARPminorCardioSignal joined AgeTech Collaborative portfolio after completing prestigious accelerator program, focused on improving accessibility of remote cardiac care for older adults.
- OMRON HealthcarecoreCardioSignal atrial fibrillation detection became available in OMRON connect app Premium Service in selected European countries, integrating medical-grade Afib detection into OMRON's digital health ecosystem.
- JISEKI HealthminorCollaboration to virtualize care paths for earlier detection of heart disease in the USA, focusing on vulnerable populations and health equity in cardiac remote patient monitoring.
Scale indicators7 records
Recent moves7 records
Expansion highlights8 records
CardioSignal competitors and assessment
Company assessmentDirect peers
- Eko Health: Digital cardiac auscultation and ECG company combining AI software with clinician-grade stethoscopes and remote monitoring — closely comparable as a digital cardiac biomarker business spanning consumer, clinical, and pharma/CRO use cases.
- FibriCheck: Belgian health tech company offering smartphone-based (PPG) atrial fibrillation detection via a CE-marked medical app and SDK — the closest direct peer to CardioSignal, competing head-to-head in European insurer-led population screening programs and SDK licensing.
- AliveCor: US-based company behind KardiaMobile, the leading consumer and clinical ECG-based Afib detection device/app — directly comparable to CardioSignal as a consumer-and-enterprise cardiac biomarker play, though AliveCor is hardware (single-lead ECG) rather than motion-sensor based.
Broad incumbents
- Withings: Connected health device maker (BPM Core, ScanWatch with ECG/Afib detection) — comparable as a consumer-grade cardiac monitoring player with overlapping insurance partnership motion, though portfolio is broader than cardiac.
- Apple (Apple Watch ECG): Apple Watch ECG and Afib detection features represent the largest-scale consumer cardiac monitoring channel globally — comparable in clinical function but a broad incumbent; CardioSignal must differentiate on accuracy and clinical validation rather than hardware.
- Philips (Cardiac Monitoring): Broad incumbent in hospital and remote cardiac monitoring (BioTelemetry acquisition) — comparable as a cardiac RPM and population health player, though operating at much larger scale across multiple care settings.
- iRhythm Technologies: Public US company behind the Zio long-term cardiac monitoring patch — comparable as a digital cardiac arrhythmia detection business serving clinicians and payers, though its modality (patch ECG) is clinical rather than consumer smartphone-based.
- Preventice Solutions (Boston Scientific): BodyGuardian remote cardiac monitoring platform acquired by Boston Scientific — comparable in remote cardiac monitoring and population-level arrhythmia detection, though focused on clinical-grade wearable patches rather than consumer smartphone apps.
Emerging players
- Qardio: Personal cardiac and vitals monitoring company (QardioArm, QardioCore ECG monitor) targeting consumer and remote patient monitoring — comparable in product breadth and D2C/clinical dual motion, though smaller and earlier-stage.
Others
- OMRON Healthcare: Both a CardioSignal partner (CardioSignal embedded in OMRON connect app Premium) and a broader incumbent in consumer/clinical blood pressure monitors and ECG devices — relevant as a competitive force in the same distribution and end-customer set.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
CardioSignal social profiles
Digital presenceCardioSignal compliance and trust
Trust signalCompliance4 records
CardioSignal financial estimates
Financial estimateRevenue estimate
Valuation estimate
CardioSignal leadership team
Management profileNumber of profiles
Profiles7 records
CardioSignal subsidiaries and ownership
Company hierarchySubsidiaries1 record
CardioSignal funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CardioSignal M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CardioSignal
What does CardioSignal do?
CardioSignal develops a CE-marked Class IIb mobile medical device software that uses smartphone gyroscope and accelerometer sensors via patented gyrocardiography to measure heart motion and detect signs of atrial fibrillation in a one-minute measurement. The company sells directly to individual consumers through a subscription app and licenses its detection technology to enterprise partners (healthcare providers, insurers, pharma/CROs, and OEMs) through its CardioSignal Inside SDK for population screening, remote patient monitoring, and clinical trial endpoints.
Is CardioSignal a public or private company?
CardioSignal is a private company. It is classified as venture growth investor backed and is currently operating.
When was CardioSignal founded?
CardioSignal was founded in 2017. It employs 11 to 50 people.
Where is CardioSignal based?
CardioSignal is headquartered in Turku, Finland, in the Europe region.
How does CardioSignal make money?
Two revenue lines are on record. Consumer App Subscriptions are the primary driver. The others are SDK Licensing (CardioSignal Inside).
Who are CardioSignal's main competitors?
Direct peers on record are Eko Health, FibriCheck and AliveCor. Broad incumbents are Withings, Apple (Apple Watch ECG), Philips (Cardiac Monitoring), iRhythm Technologies and Preventice Solutions (Boston Scientific). Qardio is listed as an emerging player. OMRON Healthcare is listed as an others.
Does CardioSignal have an API?
No public API is recorded for CardioSignal.
What industry is CardioSignal in?
CardioSignal's product category is Digital Cardiac Diagnostics Software. Its primary akta.pro industry code is HLALAGAB, Cardiology Telemedicine Platforms, with a secondary code of HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration). Its NAICS code is 334510 and its SIC code is 3845.